QUECTEL
16.5.2023 18:26:27 CEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces breaking ground for its new innovation Headquarter in Shanghai and also recently celebrated a significant milestone with the opening of its new Global Intelligent Manufacturing Center (GIMC) in Changzhou.
Delivering advanced IoT automation, the new GIMC facility features a fully functioning manufacturing production line that combines latest technologies, including edge intelligence, machine learning, robotics and machine vision solutions built with Quectel’s latest smart module technologies which significantly expands manufacturing capabilities to guarantee supply and reassure product quality for global customers. Designed and architected by a group of its own IoT experts, this state-of-the art IoT manufacturing center is equipped with the most advanced industrial automation technologies including:
- Fully automated warehouse storage system with 65,000 material cubicles, which can support 40 SMT lines material supply and operate 7x24 based on real-time workorders.
- End-to-end touchless process with Automatic Guided Vehicles to transport raw material to production lines, hand-over semi-products from SMT for testing and final packing with minimal manpower.
- 30 Fuji NXT-III SMT lines with Siemens MES monitoring system supporting production of up to 150 million modules per year.
- 85 Quectel Self Design Automatic Testing Stations with full testing log files onto each module produced.
- 40 Quectel Self Design Auto Inspection and Packing Systems.
The GIMC project started construction in September 2021 and will commence operation in 2023. The smart factory will further enhance Quectel’s production capabilities, strengthening its core competitiveness. The center occupies an area of 72,000 square meters, with a total construction space of 160,000 square meters. It is capable of manufacturing Quectel’s full range of modules, including 4G modules, 5G modules, smart modules, automotive grade modules, narrowband IoT modules, GNSS modules, Wi-Fi modules and antennas.
“Our new smart factory represents an important step toward the next generation of smart manufacturing and will guarantee both our product quality and production capacity, sufficient to meet various demanding requirements of our global customers,” said Patrick Qian, CEO of Quectel. “Applying IoT innovation to our own processes -- will not only help us enhance our industry leading quality -- it will also accelerate the expansion of the global IoT market and be a catalyst for the entire IoT eco-system.”
Quectel also recently broke ground for its new headquarters in Shanghai. “The new headquarter is designed to provide a modern, smart environment that makes it attractive for the best people to work, excel and innovate and that exceeds the highest standards in sustainability, health and wellness,” Mr. Qian continued.” It will host Quectel’s R&D center and IoT innovation showroom and will bring together some of the world’s greatest engineers and IoT leaders to accelerate innovation and drive the future of IoT”. The new headquarter of approximately 100,000 square meters will serve as a central hub for administrative and research and development functions but will also offer a wide range of amenities including sports facilities, conference spaces, outdoor gardens, catering services, and ample parking facilities. The company plans to officially inaugurate and begin operations at the new headquarters in 2025.
Founded in 2010, Quectel has consistently maintained rapid development and has become a leading global IoT provider of solutions covering cellular modules, Wi-Fi modules, smart modules, automotive modules, GNSS modules, antennas as well as connectivity and certification services.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 6,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas, services and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005801/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom